Open AccessAdjuvant High‐Dose Interferon‐α for Resected Melanoma in a Patient with HIV Infection
Author(s) -
Saba Nakhle S.,
George Thomas J.,
Boulmay Brian C.
Publication year - 2010
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2009-0335
Subject(s) - medicine , adjuvant , melanoma , immunotherapy , adjuvant therapy , interferon , human immunodeficiency virus (hiv) , oncology , surgery , immunology , cancer , cancer research
Adjuvant interferon (IFN)‐α remains the standard adjuvant therapy for intermediate and high‐risk melanoma after definitive surgical resection. Data addressing the role and safety of adjuvant immunotherapy in HIV‐infected patients with melanoma are lacking. We report on an HIV + patient who received IFN‐α as adjuvant treatment for high‐risk melanoma. To our knowledge, this is the first reported case of such an approach.